^Cao YJ, Surowy CS, Puttfarcken PS (March 2005). "Nicotinic acetylcholine receptor-mediated [3H]dopamine release from hippocampus". The Journal of Pharmacology and Experimental Therapeutics. 312 (3): 1298–304.
doi:
10.1124/jpet.104.076794.
PMID15542623.
S2CID20437091.
^Gohlke H, Gündisch D, Schwarz S, Seitz G, Tilotta MC, Wegge T (February 2002). "Synthesis and nicotinic binding studies on enantiopure diazine analogues of the novel (2-chloro-5-pyridyl)-9-azabicyclo[4.2.1]non-2-ene UB-165". Journal of Medicinal Chemistry. 45 (5): 1064–72.
doi:
10.1021/jm010936y.
PMID11855986.
^Sharples CG, Karig G, Simpson GL, Spencer JA, Wright E, Millar NS, et al. (July 2002). "Synthesis and pharmacological characterization of novel analogues of the nicotinic acetylcholine receptor agonist (+/-)-UB-165". Journal of Medicinal Chemistry. 45 (15): 3235–45.
doi:
10.1021/jm020814l.
PMID12109907.
^Sutherland A, Gallagher T, Sharples CG, Wonnacott S (March 2003). "Synthesis of two fluoro analogues of the nicotinic acetylcholine receptor agonist UB-165". The Journal of Organic Chemistry. 68 (6): 2475–8.
doi:
10.1021/jo026698b.
PMID12636420.
^Karig G, Large JM, Sharples CG, Sutherland A, Gallagher T, Wonnacott S (September 2003). "Synthesis and nicotinic binding of novel phenyl derivatives of UB-165. Identifying factors associated with alpha7 selectivity". Bioorganic & Medicinal Chemistry Letters. 13 (17): 2825–8.
doi:
10.1016/S0960-894X(03)00594-8.
PMID14611837.